Adicet Bio Net Income
| ACET Stock | USD 7.25 0.22 3.13% |
As of the 11th of February 2026, Adicet Bio shows the Risk Adjusted Performance of (0.09), mean deviation of 3.44, and Standard Deviation of 4.42. Adicet Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Adicet Bio Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 2.1386 | Earnings Share (20.03) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -105.4 M | -100.1 M | |
| Net Loss | -105.4 M | -110.7 M | |
| Net Loss | (24.53) | (23.30) | |
| Net Income Per E B T | 0.90 | 0.60 |
Adicet | Net Income | Build AI portfolio with Adicet Stock |
The evolution of Net Income for Adicet Bio provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Adicet Bio compares to historical norms and industry peers.
Latest Adicet Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Adicet Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Adicet Bio financial statement analysis. It represents the amount of money remaining after all of Adicet Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Adicet Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adicet Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (117.12 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Adicet Net Income Regression Statistics
| Arithmetic Mean | (34,819,654) | |
| Coefficient Of Variation | (159.04) | |
| Mean Deviation | 45,889,239 | |
| Median | (28,138,000) | |
| Standard Deviation | 55,376,203 | |
| Sample Variance | 3066.5T | |
| Range | 171.7M | |
| R-Value | (0.90) | |
| Mean Square Error | 593.1T | |
| R-Squared | 0.82 | |
| Slope | (9,922,240) | |
| Total Sum of Squares | 49064.4T |
Adicet Net Income History
Other Fundumenentals of Adicet Bio
Adicet Bio Net Income component correlations
Adicet Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Adicet Bio is extremely important. It helps to project a fair market value of Adicet Stock properly, considering its historical fundamentals such as Net Income. Since Adicet Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adicet Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adicet Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Providers & Services market expansion? Will Adicet introduce new products? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Adicet Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Adicet Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Adicet Bio's market price to deviate significantly from intrinsic value.
Understanding that Adicet Bio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adicet Bio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Adicet Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Adicet Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Adicet Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Adicet Bio.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Adicet Bio on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Adicet Bio or generate 0.0% return on investment in Adicet Bio over 90 days. Adicet Bio is related to or competes with Lite Strategy, IO Biotech, Tscan Therapeutics, Adagene, NRX Pharmaceuticals, Werewolf Therapeutics, and Immunic. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and... More
Adicet Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Adicet Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Adicet Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 21.12 | |||
| Value At Risk | (7.60) | |||
| Potential Upside | 6.19 |
Adicet Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adicet Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Adicet Bio's standard deviation. In reality, there are many statistical measures that can use Adicet Bio historical prices to predict the future Adicet Bio's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | 0.6532 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Adicet Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Adicet Bio February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 0.6632 | |||
| Mean Deviation | 3.44 | |||
| Coefficient Of Variation | (822.51) | |||
| Standard Deviation | 4.42 | |||
| Variance | 19.54 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | 0.6532 | |||
| Maximum Drawdown | 21.12 | |||
| Value At Risk | (7.60) | |||
| Potential Upside | 6.19 | |||
| Skewness | (0.23) | |||
| Kurtosis | 0.2334 |
Adicet Bio Backtested Returns
Adicet Bio secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. Adicet Bio exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adicet Bio's Mean Deviation of 3.44, standard deviation of 4.42, and Risk Adjusted Performance of (0.09) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.84, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Adicet Bio are expected to decrease at a much lower rate. During the bear market, Adicet Bio is likely to outperform the market. At this point, Adicet Bio has a negative expected return of -0.53%. Please make sure to confirm Adicet Bio's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Adicet Bio performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.31 |
Below average predictability
Adicet Bio has below average predictability. Overlapping area represents the amount of predictability between Adicet Bio time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Adicet Bio price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current Adicet Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.26 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Adicet Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Adicet Bio reported net income of (117.12 Million). This is 134.32% lower than that of the Health Care Providers & Services sector and 267.21% lower than that of the Health Care industry. The net income for all United States stocks is 120.51% higher than that of the company.
Adicet Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adicet Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics of similar companies.Adicet Bio is currently under evaluation in net income category among its peers.
Adicet Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adicet Bio from analyzing Adicet Bio's financial statements. These drivers represent accounts that assess Adicet Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adicet Bio's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 541.4M | 367.3M | 81.4M | 84.5M | 97.2M | 92.3M | |
| Enterprise Value | 284.8M | 130.6M | (57.4M) | 45.3M | 52.0M | 49.4M |
Adicet Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Adicet Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Adicet Bio's managers, analysts, and investors.Environmental | Governance | Social |
Adicet Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Adicet Bio that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Adicet Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adicet Bio's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 706.3 K | Alyeska Investment Group, L.p. | 2025-06-30 | 655.7 K | Rbf Llc | 2025-06-30 | 617.3 K | Blackrock Inc | 2025-06-30 | 599.5 K | Millennium Management Llc | 2025-06-30 | 592.3 K | Two Sigma Advisers, Llc | 2025-06-30 | 566 K | Dafna Capital Management Llc | 2025-06-30 | 540 K | Two Sigma Investments Llc | 2025-06-30 | 512.8 K | Citadel Advisors Llc | 2025-06-30 | 460.4 K | Orbimed Advisors, Llc | 2025-06-30 | 11.4 M | Tang Capital Management Llc | 2025-06-30 | 8.2 M |
Adicet Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | (19.21 M) | ||||
| Shares Outstanding | 9.6 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 44.55 % | ||||
| Number Of Shares Shorted | 690.55 K | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 9.72 X | ||||
| Gross Profit | 24.99 M | ||||
| EBITDA | (110.65 M) | ||||
| Net Income | (117.12 M) | ||||
| Cash And Equivalents | 260.64 M | ||||
| Cash Per Share | 6.11 X | ||||
| Total Debt | 17.23 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.10 X | ||||
| Book Value Per Share | 19.04 X | ||||
| Cash Flow From Operations | (92.38 M) | ||||
| Short Ratio | 3.26 X | ||||
| Earnings Per Share | (20.03) X | ||||
| Price To Earnings To Growth | 0.82 X | ||||
| Target Price | 61.5 | ||||
| Number Of Employees | 152 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 68.45 M | ||||
| Total Asset | 220.22 M | ||||
| Retained Earnings | (497.89 M) | ||||
| Working Capital | 160.74 M | ||||
| Current Asset | 352.66 M | ||||
| Current Liabilities | 98.91 M | ||||
| Five Year Return | 3.23 % | ||||
| Net Asset | 220.22 M |
About Adicet Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.